# Testing Olaparib and AZD6738 in IDH1 and IDH2 Mutant Tumors

> **NCT03878095** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **National Cancer Institute (NCI)** · enrollment: 24 (actual)

## Conditions studied

- Malignant Solid Neoplasm
- Refractory Cholangiocarcinoma
- Refractory Malignant Solid Neoplasm

## Interventions

- **PROCEDURE:** Biopsy Procedure
- **PROCEDURE:** Biospecimen Collection
- **PROCEDURE:** Bone Marrow Aspiration
- **PROCEDURE:** Bone Marrow Biopsy
- **DRUG:** Ceralasertib
- **PROCEDURE:** Computed Tomography
- **PROCEDURE:** Magnetic Resonance Imaging
- **DRUG:** Olaparib

## Key facts

- **NCT ID:** NCT03878095
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2020-01-30
- **Primary completion:** 2025-03-12
- **Final completion:** 2026-07-10
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2026-04-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03878095

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03878095, "Testing Olaparib and AZD6738 in IDH1 and IDH2 Mutant Tumors". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT03878095. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*